Table 3:

Association between MenB-4C vaccination and gonorrhoea or gonorrhoea and chlamydia co-infection compared with chlamydia assuming a duration of vaccine-induced protection of 6 months

	Gonorrhoea				Gonorrhoea and chlamydia co-infection
	UPR (95% CI)	p value	APR (95% CI)	p value	UPR (95% CI)	p value	APR (95% CI)	p value
MenB-4C vaccination status
Complete vaccination*	0.58 (0.48-0.71)	<0.0001	0.61 (0.49–0.77)	<0.0001	0.92 (0.73–1.16)	0.47	0.87 (0.66–1.13)	0.31
Partial vaccinationt	0.70 (0.62-0.78)	<0.0001	0.66 (0.58–0.76)	<0.0001	1.10 (0.95–1.26)	0.21	0.97 (0.83–1.15)	0.80
Unvaccinated‡	1 (ref)	..	1 (ref)	..	1 (ref)	..	1 (ref)	..
Race or ethnicity
Black, non-Hispanic	0.95 (0.88–1.02)	0.26	0.94 (0.88–1.02)	0.17	1.38 (1.22–1.54)	<0.0001	1.37 (1.22–1.55)	<0.0001
Hispanic	0.68 (0.63–0.74)	<0.0001	0.72 (0.67–0.79)	<0.0001	0.84 (0.74–0.96)	0.011	0.88 (0.77–1.01)	0.071
Other§	0.94 (0.84-1.06)	0.46	0.98 (0.87–1.11)	0.79	1.31 (1.08–1.56)	0.0040	1.33 (1.11–1.61)	0.0018
White, non-Hispanic	1 (ref)	..	1 (ref)	..	1 (ref)	..	1 (ref)	..
Gender
Male	2.68 (2.59–2.78)	<0.0001	2.69 (2.58–2.80)	<0.0001	2.12 (2.01–2.23)	<0.0001	2.10 (1.98–2.23)	<0.0001
Female	1 (ref)	..	1 (ref)	..	1 (ref)	..	1 (ref)	..
Jurisdiction
New York City, NY, USA	0.74 (0.71-0.77)	<0.0001	1.01 (0.97–1.06)	0.41	0.71 (0.68–0.75)	<0.0001	0.99 (0.93–1.05)	0.78
Philadelphia, PA, USA	1 (ref)	..	1 (ref)	..	1 (ref)	..	1 (ref)	..

APR=adjusted prevalence ratio. UPR=unadjusted prevalence ratio. STI=sexually transmitted infection.

^*Receipt of two doses of MenB-4C doses separated by 30–180 days.

^†Receipt of one MenB-4C dose.

^‡Never vaccinated against Neisseria meningitidis serogroup B with MenB-4C or MenB-FHbp (ie, MenB vaccine naive or STI occurred before first MenB-4C vaccine dose).

^§Asian, American Indian, Native Hawaiian or Pacific Islander, other race, or two or more races.